News

NEPA is an oral fixed combination of a novel NK1receptor antagonist (netupitant) and the best-in-class 5-HT3receptor antagonist palonosetron, already approved in the USA with the trade name AKYNZEO

This decision result ed from a vaccine portfolio prioritization process to ensure that Takeda’s R&D resource s are directed toward the highest – impact programs for public health.

The agreement grants Nicox exclusive rights to commercialize all three products in Europe (including Eastern Europe), Middle East and Africa (EMEA). Nicox expects to file European Marketing Authorizations

Self-administered subcutaneously, Hizentra delivers consistent levels of immunoglobulin G (IgG) regardless of dosing schedule. Hizentra, the first and only 20 percent subcutaneous immunoglobulin, received FDA approval in March

This study is the first of a number of preclinical studies that will be performed. These studies are designed to test the safety, efficacy and dosing of Melligen

In multiple Phase II trials, TD-4208 has shown positive top-line results in COPD patients, and recently the FDA had agreed to the design of the Phase III registrational

Intellipharmaceutics currently has an abbreviated new drug application (ANDA) for the candidate and yet to receive approval from the US Food and Drug Administration (FDA). Subject to certain

As part of the deal, Viking will provide financial support and access to its proprietary library of thyroid beta agonists for AMC scientists to evaluate in preclinical models

The company said that Pazeo solution is dosed one drop daily, and was approved with efficacy data at 24 hours, post dose. The approval was based on data